FI3661503T3 - PARANTUNEEN AKTIIVISUUDEN HAPPAMASSA pH:SSA OMAAVIA SIENILÄÄKKEITÄ - Google Patents

PARANTUNEEN AKTIIVISUUDEN HAPPAMASSA pH:SSA OMAAVIA SIENILÄÄKKEITÄ Download PDF

Info

Publication number
FI3661503T3
FI3661503T3 FIEP18755632.9T FI18755632T FI3661503T3 FI 3661503 T3 FI3661503 T3 FI 3661503T3 FI 18755632 T FI18755632 T FI 18755632T FI 3661503 T3 FI3661503 T3 FI 3661503T3
Authority
FI
Finland
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
administered
Prior art date
Application number
FIEP18755632.9T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Gonzalez David A Angulo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3661503(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of FI3661503T3 publication Critical patent/FI3661503T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP18755632.9T 2017-08-04 2018-07-31 PARANTUNEEN AKTIIVISUUDEN HAPPAMASSA pH:SSA OMAAVIA SIENILÄÄKKEITÄ FI3661503T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762541370P 2017-08-04 2017-08-04
PCT/US2018/044619 WO2019028034A1 (en) 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic ph

Publications (1)

Publication Number Publication Date
FI3661503T3 true FI3661503T3 (fi) 2022-12-15

Family

ID=63209698

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18755632.9T FI3661503T3 (fi) 2017-08-04 2018-07-31 PARANTUNEEN AKTIIVISUUDEN HAPPAMASSA pH:SSA OMAAVIA SIENILÄÄKKEITÄ

Country Status (26)

Country Link
US (3) US11534433B2 (cg-RX-API-DMAC7.html)
EP (3) EP4169514B1 (cg-RX-API-DMAC7.html)
JP (1) JP7214714B2 (cg-RX-API-DMAC7.html)
KR (1) KR102807716B1 (cg-RX-API-DMAC7.html)
CN (2) CN118542868A (cg-RX-API-DMAC7.html)
AU (2) AU2018309718B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020002290A2 (cg-RX-API-DMAC7.html)
CA (1) CA3071940A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125690T1 (cg-RX-API-DMAC7.html)
DK (1) DK3661503T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090445A1 (cg-RX-API-DMAC7.html)
ES (2) ES2932658T3 (cg-RX-API-DMAC7.html)
FI (1) FI3661503T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221414T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060508T2 (cg-RX-API-DMAC7.html)
LT (1) LT3661503T (cg-RX-API-DMAC7.html)
MA (1) MA49751B1 (cg-RX-API-DMAC7.html)
MD (1) MD3661503T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020001399A (cg-RX-API-DMAC7.html)
PL (1) PL3661503T3 (cg-RX-API-DMAC7.html)
PT (1) PT3661503T (cg-RX-API-DMAC7.html)
RS (1) RS63746B1 (cg-RX-API-DMAC7.html)
SI (1) SI3661503T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200461T1 (cg-RX-API-DMAC7.html)
TW (1) TWI805600B (cg-RX-API-DMAC7.html)
WO (1) WO2019028034A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020228036B2 (en) * 2019-02-27 2025-08-07 Scynexis, Inc. Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
BRPI0912074B1 (pt) * 2008-08-12 2021-08-03 Merck Sharp & Dohme Corp Composto e composição farmacêutica
PT3247711T (pt) 2015-01-19 2022-05-16 Scynexis Inc Novos sais e polimorfos de scy-078
JP7263313B2 (ja) * 2017-04-10 2023-04-24 サイネクシス,インコーポレーテッド 併用される抗真菌剤

Also Published As

Publication number Publication date
US20200390751A1 (en) 2020-12-17
CN118542868A (zh) 2024-08-27
EP4169514B1 (en) 2026-01-28
SMT202200461T1 (it) 2023-01-13
MD3661503T2 (ro) 2023-01-31
KR20200044823A (ko) 2020-04-29
CA3071940A1 (en) 2019-02-07
AU2024227501A1 (en) 2024-11-07
TWI805600B (zh) 2023-06-21
BR112020002290A2 (pt) 2020-09-08
US20260000656A1 (en) 2026-01-01
HUE060508T2 (hu) 2023-03-28
JP7214714B2 (ja) 2023-01-30
HRP20221414T1 (hr) 2023-01-20
PL3661503T3 (pl) 2023-01-09
CN111093655A (zh) 2020-05-01
AU2018309718A1 (en) 2020-02-27
SI3661503T1 (sl) 2023-01-31
MX2020001399A (es) 2020-08-06
MA49751B1 (fr) 2022-12-30
TW201919476A (zh) 2019-06-01
LT3661503T (lt) 2022-12-12
WO2019028034A1 (en) 2019-02-07
PT3661503T (pt) 2022-12-13
RS63746B1 (sr) 2022-12-30
EP4169514A1 (en) 2023-04-26
EP3661503A1 (en) 2020-06-10
JP2020529999A (ja) 2020-10-15
DK3661503T3 (da) 2022-12-12
MA49751A (fr) 2020-06-10
US20230364067A1 (en) 2023-11-16
KR102807716B1 (ko) 2025-05-13
CY1125690T1 (el) 2026-02-25
EP3661503B1 (en) 2022-09-07
EP4732902A3 (en) 2026-07-22
US11534433B2 (en) 2022-12-27
ES2932658T3 (es) 2023-01-23
EA202090445A1 (ru) 2020-06-23
EP4732902A2 (en) 2026-04-29
AU2018309718B2 (en) 2024-07-25
EP4169514C0 (en) 2026-01-28
ES3068719T3 (en) 2026-06-02

Similar Documents

Publication Publication Date Title
HRP20231276T1 (hr) Inhibitor egfr-a za liječenje raka
FI3805222T3 (fi) 7-bentsyyli-4-(2-metyylibentsyyli)-2,4,6,7,8,9-heksahydroimidatso[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onijohdannaisia, niiden suoloja ja niiden käyttö hoidossa
RU2011135417A (ru) Галеновы препараты органических соединений
IL298998B2 (en) Pharmaceutical formulations of a hif hydroxylase inhibitor
HRP20221414T1 (hr) Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph
Yang et al. Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer
JP2020529999A5 (cg-RX-API-DMAC7.html)
SK150797A3 (en) Antifungal composition
WO2007110753A3 (en) Extended release dosage forms of metoprolol
FI3173071T4 (fi) Maropitantin formulaatio
EP2849746B1 (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and meloxicam
EP2849747B1 (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar
AU2007321218A1 (en) Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents
WO2007016128A3 (en) Magnesium salt proton pump inhibitor dosage forms
JP2016505628A5 (cg-RX-API-DMAC7.html)
CN104003948A (zh) 一类氮唑类化合物及其制备方法和应用
JP2017057199A5 (cg-RX-API-DMAC7.html)
Zhu et al. New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents
JP2022519500A5 (cg-RX-API-DMAC7.html)
CN101288661A (zh) 硝酸芬替康唑阴道泡腾片及其制备方法
US10463643B2 (en) Composition comprising a compound from the family of avermectins and doxycycline for the treatment of rosacea
HK40109129A (en) Antifungal agents with enhanced activity in acidic ph
RU2015142290A (ru) Капсулы для комплексной терапии заболеваний мочевыделительной системы
SG193328A1 (en) Solid preparation
CN113631165A (zh) 用于治疗或预防肺囊虫属肺炎的三萜类抗真菌剂